Last reviewed · How we verify
polyethylene glycol in combination with lubiprostone
Polyethylene glycol in combination with lubiprostone is a marketed product developed by the Department of Medical Services Ministry of Public Health of Thailand, currently holding a position in the therapeutic market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports its competitive advantage. The primary risk lies in the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | polyethylene glycol in combination with lubiprostone |
|---|---|
| Also known as | NIFLEC in combination with Amitiza |
| Sponsor | Department of Medical Services Ministry of Public Health of Thailand |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Colon Preparation With 2L PEG in Combination With Lubiprostone vs 4L PEG (PHASE4)
- Efficacy of Lubiprostone in Combination With Standard PEG Preparation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: